Liberty Mutual Group Asset Management Inc. Vertex Pharmaceuticals Inc Transaction History

Liberty Mutual Group Asset Management Inc.

$660 Million
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $1.55 Million - $1.96 Million	-10,186 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $20,109 - $23,454	138 Added 1.37%	10,186 $1.73 Million
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $5,216 - $5,910	-38 Reduced 0.38%	10,048 $1.51 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $1.49 Million - $1.64 Million	10,086	10,086 $1.53 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$11 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.47 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.71 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.83 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.68 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Liberty Mutual Group Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Liberty Mutual Group Asset Management Inc. with notifications on news.

Account